Detection of previous exposure or immunity to hepatitis A infection
Chemiluminescent Microparticle Immunoassay (CMIA)
Anti-HAV
Anti-HAV IgG
Anti-Hepatitis A
Anti-Hepatitis A IgG
HAVAB-G
Hepatitis A antibody
Hepatitis A IgG Antibody
Hepatitis A IgG
HAIGG
Serum
Date of collection is required.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Centrifuge blood collection tube per collection tube manufacturer's instructions (eg, centrifuge and aliquot within 2 hours of collection for BD Vacutainer tubes).
2. Aliquot serum into plastic vial.
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)
0.4 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 8 days | |
Ambient | 4 days |
Detection of previous exposure or immunity to hepatitis A infection
Hepatitis A virus (HAV) is endemic throughout the world, occurring most commonly in areas of poor hygiene and low socioeconomic conditions. The virus is transmitted primarily by the fecal-oral route and spread by close person-to-person contact as well as by food and waterborne epidemics. Outbreaks frequently occur in overcrowded situations and high-density institutions and centers, such as prisons and healthcare or daycare centers. Viral spread by parenteral routes (eg, exposure to blood) is possible, but rare, because infected individuals are viremic for a short period of time (usually <3 weeks). There is little or no evidence of transplacental transmission from mother to fetus or transmission to newborn during delivery.
In most cases of acute viral hepatitis A, IgM antibodies to HAV (anti-HAV IgM) are detectable by the time symptoms occur, usually 15 to 45 days after exposure. HAV-specific IgM antibody level in serum usually falls to an undetectable level by 6 months after acute infection. HAV-specific IgG antibody (anti-HAV IgG) level in serum rises quickly once the virus is cleared and may persist for many years.
This assay detects the presence of hepatitis A virus (HAV)-specific IgG antibody in serum.
A negative result indicates the absence of HAV-specific IgG antibody, implying no past exposure or immunity to HAV infection.
A positive result indicates the presence of HAV-specific IgG antibody from either vaccination or past exposure to hepatitis A virus.
Passively acquired IgG antibody from recent immune globulin administration or transfusion may result in transiently positive test results.
The presence of heterophilic antibodies or human antimouse antibodies (in patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy) in serum may interfere with the assay and cause erroneous results (false-positive or false-negative).
Specimens from individuals with anti-Escherichia coli, anti-cytomegalovirus (CMV), or hemodialysis patients may cross-react with this assay.
Performance characteristics have not been established for the following specimen characteristics:
-Grossly icteric (total bilirubin level of >20 mg/dL)
-Grossly hemolyzed (hemoglobin level of >500 mg/dL)
-Grossly lipemic (triolein level >3,000 mg/dL)
-Containing particulate matter
-Cadaveric specimens
1. Nelson NP, Weng MK, Hofmeister MG, et al: Prevention of hepatitis A virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 3;69(5):1-38. Erratum in MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):294
2. de Paula VS: Laboratory diagnosis of hepatitis A. Future Virology. 2012;7(5):461-472
3. Webb GW, Kelly S, Dalton HR: Hepatitis A and hepatitis E: clinical and epidemiological features, diagnosis, treatment, and prevention. Clin Microbiol Newsl. 2020 Nov 1;42(21):171-179
The ARCHITECT HAVAB-G assay is an automated immunoassay designed for the qualitative detection of hepatitis A virus (HAV)-specific IgG antibody in human serum using chemiluminescent microparticle immunoassay method. Patient's sample, assay diluent, and HAV-coated paramagnetic microparticles are combined first in a reaction well. Anti-HAV IgG present in the patient sample binds to the HAV-coated microparticles. After washing, the acridinium-labeled antihuman IgG conjugate is added to bind to anti-HAV IgG. Following another wash cycle, pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units. The presence or absence of anti-HAV IgG in the patient sample is determined by comparing the chemiluminescent signal in the reaction to the cutoff signal determined from an ARCHITECT HAVAB-G calibration. Specimens with signal to cutoff (S/Co) values at or above 1.00 are considered positive for anti-HAV IgG. Specimens with S/Co values below 1.00 are considered negative.(Package insert: HAVAB-G. Abbott Laboratories; 04/2020)
Monday through Saturday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
86708
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
HAIGG | Hepatitis A IgG Ab, S | 40724-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
HAIGG | Hepatitis A IgG Ab, S | 40724-7 |